Spots Global Cancer Trial Database for Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
Official Title: Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive
Study ID: NCT00556127
Study Description
Brief Summary: The purpose of this trial was to evaluate efficacy and safety of adding Rituximab to dose-dense and High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as first line treatment in young patients with DLBCL at Intermediate-High and High risk aaIPI score
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Az. Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, , Italy
Ospedale Regionale, Divisione di Oncologia,, Aosta, , Italy
Azienda Ospedaliera Ospedale Policlinico Consorziale, Bari, , Italy
Osp. degli Infermi, Biella, , Italy
Spedali Civili, Brescia, , Italy
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, , Italy
Ospedale S. Gerardo, Monza, , Italy
Osp. maggiore della Carità, Novara, , Italy
Università degli Studi Policlinico Monteluce, Perugia, , Italy
Divisione di Medicina, Ospedale Generale E. Agnelli, Pinerolo, Torino, , Italy
Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, , Italy
Osp. S. Giovanni Battista "Molinette", Torino, , Italy
Ospedale di Chivasso e Ivrea, Torino, , Italy
Stabilimento Ospedaliero Ciriè -, Torino, , Italy
Contact Details
Name: Umberto Vitolo, MD
Affiliation: S.C. Ematologia II - OSP.S. GIOV.BATTISTA MOLINETTE - TORINO (TO) -
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
